Stroke drug bleeding risks revealed in new study
NCT ID NCT06337175
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study in 600 stroke patients in the Middle East looked at what factors might predict different types of brain bleeding after treatment with the clot-busting drug alteplase. Researchers analyzed patient characteristics, how quickly the drug was given, and stroke risk factors to see which ones were linked to bleeding. The goal was to better understand who is at higher risk, which could help doctors make safer treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
alteplase (a clot-busting drug)
What this could lead to
If successful, this could help doctors identify which stroke patients are at higher risk of brain bleeding after receiving alteplase, potentially improving treatment safety.
What could go wrong
This is a completed observational analysis, not a new treatment trial. The findings may not apply to all populations or change current guidelines.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kafr Elsheikh University Hospital
Kafr ash Shaykh, 33155, Egypt